← 返回

旁观者 CD4⁺ T 细胞浸润人类肿瘤并具有独特表型

英文原题:Bystander CD4(+) T cells infiltrate human tumors and are phenotypically distinct.

查看英文原题

Bystander CD4(+) T cells infiltrate human tumors and are phenotypically distinct.

PubMed 2022/01/02(内容时间) Oncoimmunology Q1 · IF 6.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤特异性T细胞可能是有效免疫检查点阻断疗法的关键基础。然而,大多数研究聚焦于Treg细胞和CD8+TIL(肿瘤浸润淋巴细胞)(TILs)。

在此,我们研究人肺癌和结直肠癌中的CD4+TILs,并观察到在两种癌症类型中,非Treg CD4+TILs平均占CD4+TILs总数的70%以上。利用包括质谱流式细胞术在内的高维分析,我们揭示CD4+TILs在每个肿瘤内以及不同患者之间具有表型异质性。一致地,我们发现不同的CD4+TILs亚群表现出效应细胞、组织驻留记忆(Trm)或耗竭细胞(表达PD-1、CTLA-4和CD39)的特征。在两种癌症类型中,CD39-非Treg CD4+TILs的频率与CD39-CD8+TILs的频率强烈相关,我们和其他人此前已表明后者富集了针对癌症无关抗原(旁观者)特异性的细胞。在离体实验中,我们证明CD39-CD4+TILs可以对癌症无关抗原具有特异性,例如HCMV表位。

总体而言,我们的发现强调CD4+TILs也可以识别癌症无关抗原,并表明测量CD39表达是量化或分离旁观者CD4+T细胞的一种直接方法。

展开英文摘要原文

Tumor-specific T cells likely underpin effective immune checkpoint-blockade therapies. Yet, most studies focus on Treg cells and CD8 + tumor-infiltrating lymphocytes (TILs).

Here, we study CD4 + TILs in human lung and colorectal cancers and observe that non-Treg CD4 + TILs average more than 70% of total CD4 + TILs in both cancer types. Leveraging high dimensional analyses including mass cytometry, we reveal that CD4 + TILs are phenotypically heterogeneous, within each tumor and across patients. Consistently, we find different subsets of CD4 + TILs showing characteristics of effectors, tissue resident memory (Trm) or exhausted cells (expressing PD-1, CTLA-4 and CD39).

In both cancer types, the frequencies of CD39 - non-Treg CD4 + TILs strongly correlate with frequencies of CD39 - CD8 + TILs, which we and others have previously shown to be enriched for cells specific for cancer-unrelated antigens (bystanders). Ex-vivo , we demonstrate that CD39 - CD4 + TILs can be specific for cancer-unrelated antigens, such as HCMV epitopes.

Overall, our findings highlight that CD4 + TILs can also recognize cancer-unrelated antigens and suggest measuring CD39 expression as a straightforward way to quantify or isolate bystander CD4 + T cells.

论文信息

作者
Li S、Zhuang S、Heit A、Koo SL、Tan AC、Chow IT、Kwok WW、Tan IB
单位
Fred Hutch Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, Washington, USA.United States
文献类型
非美国政府资助研究
期刊
Oncoimmunology2022
原文标识
PubMed 36524209 · DOI 10.1080/2162402X.2021.2012961